Marth Research Laboratory at UC Santa Barbara

Jamey D. Marth, Ph.D.
Principal Investigator
Director and Professor, Center for Nanomedicine
John Carbon Endowed Chair in Molecular Biology and Biochemistry
Duncan and Suzanne Mellichamp Endowed Chair in Systems Biology
2324 Life Sciences Bldg., MCDB
University of California, Santa Barbara 93106-9625

Phone: (805) 893-7319
Fax: (805) 893-7322
Emial: jmarth@sanfordburnham.org, jmarth@lifesci.ucsb.edu

Jamey Marth is the Director of the UCSB-SBMRI Center for Nanomedicine, and a Professor of the University of California, Santa Barbara and of the Sanford-Burnham Medical Research Institute. Dr. Marth is the inaugural holder of the John Carbon Endowed Chair of Biochemistry and Molecular Biology and the Duncan and Suzanne Mellichamp Endowed Chair of Systems Biology at UC Santa Barbara. Dr. Marth is also a faculty member of the Department of Molecular, Cellular, and Developmental Biology, and a member of the Biomolecular Science and Engineering program at UC Santa Barbara. He received a Ph.D. degree in Pharmacology from the University of Washington in Seattle and studied in the laboratories of Dr. Roger M. Perlmutter, currently Executive Vice-President of Research and Development at Amgen; and the late Dr. Edwin G. Krebs, a 1992 Nobel laureate in Physiology or Medicine and Professor Emeritus at University of Washington in Seattle. Dr. Marth was recruited to UC San Diego in 1995 by Dr. George Palade, whom was a 1974 Nobel laureate in Physiology or Medicine. Dr. Marth was an Investigator of the Howard Hughes Medical Institute and Professor in the Department of Cellular and Molecular Medicine at UC San Diego prior to his current position.Research in the Marth laboratory combines the biological and physical sciences in the context of cell biology and nanomedicine to discover the origins and mechanisms of common grievous diseases. Identifying the causes of disease increases knowledge of fundamental biology while answering medically important questions that have defied resolution. These discoveries are then applied to develop more sensitive diagnostics and effective therapeutics that can achieve disease prevention, treatment, and ultimately a cure. Studies in the laboratory currently span autoimmune disease, cancer, diabetes, neurodegenerative syndromes, sepsis and infectious disease. Previous research by the laboratory identified biomarkers and causes of disease for which no diagnostics or therapeutics presently exist. The laboratory develops biomedical methodologies that address unmet research and therapeutic needs, from Cre-lox mutagenesis to diagnostic and therapeutic nanodevices. Current efforts include the generation of novel disease-targeting nanoparticle therapeutics and the incorporation of microfluidic and microarray platforms to achieve an integrative analysis of the fundamental cellular components that control health and disease. Nanomedicine provides an interdisciplinary research and development platform that is increasingly needed to detect and intervene in the cellular dysfunction that causes disease.